Conducting Clinical Trials of the Medicine "Rutan Tablets 0.1g" No. 10 in the Complex Therapy of COVID-19
Patients With COVID-19
About this trial
This is an interventional treatment trial for Patients With COVID-19 focused on measuring COVID-19, SARS-CoV-2, Rutan
Eligibility Criteria
Inclusion Criteria: Providing a signed and dated informed consent form. Declared willingness to comply with all study procedures and availability during the study. Man or woman over the age of 18. Patients with PCR-confirmed COVID-19 with mild/moderate disease. U07.1. Ability to take oral medications and willingness to adhere to the regimen. For women of childbearing potential: use of highly effective contraceptives for at least 1 month before screening and agree to use such a method during study participation and for an additional 4 weeks after the end. For men of reproductive potential: use condoms or other methods to ensure effective contraception with a partner. Agree to adhere to the lifestyle principles throughout the study period. Exclusion Criteria: Pregnancy or lactation. Severe form of COVID-19 disease. U07.1. Treatment with another investigational drug. Individual intolerance to the drug. The occurrence of any allergic reactions. Weighting of the general state of health of the patient and the transition to a severe form of the disease.
Sites / Locations
- Erkin Musabaev
Arms of the Study
Arm 1
Arm 2
Experimental
Other
The main group receiving the drug "Rutan 0.1" and
The control group not receiving Rutan 0.1
The main group will receive the drug "Rutan 0.1"
The control group will not be given the study drug Rutan 0.1